中国实用内科杂志2012，Vol.32Issue(11)：862-864,后插1,4.
不同供者来源异基因造血干细胞移植治疗恶性血液病69例疗效和预后分析
Analysis of efficacy and prognosis of allogeneic hematopoietic stem cell transplantation from different donors in treatment of hematologic malignancies.
摘要
Abstract
Objective To investigate the clinical efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) from unrelated donors and that from related donors in treatment of hematologic malignancies. Methods Between April 2006 and December 2011 ,69 patients received allo-HSCT were retrospectively analyzed and divided into unrelated donors ( URD group, n = 30 ) and sibling donors ( RD group, n = 39 ) according to the sources of hematopoietic stem cell ( HsC ) . The long-term following-up results including the median time of graft survival of neutrophils and platelets, engraftment, rates of graft -versus-host disease (GVHD) and infection, relapse and overall survival rate were analyzed statistically in the two groups. Results 69 patients achieved complete donor engraftment, with the median time of graft survival of neutrophils and platelets being 11 d vs 10 d and 15 d vs 14 d in URD and RD groups, respectively ( both P > 0. 05). Acute GVHD ( aGVHD) occurred in a total of 33 patients. Notably, there were 12 cases of Ⅰ ~ Ⅱ GVHD (40. 0% ) and 7 cases of Ⅲ ~ Ⅳ GVHD (23. 3% ) in URD group. While in RD group,there were 12 cases of Ⅰ ~Ⅱ GVHD (30. 8% ) and 2 cases of Ⅰ ~ Ⅳ GVHD (5. 1% ). No difference was found in occurrence rate of Ⅰ - Ⅱ GVHD between URD and RD groups ( P = 0. 455 ) , nor in that of Ⅰ ~ Ⅳ GVHD ( P - 0. 035). The five-year total survival rates were 56. 7 % and 64. 1 % in URD and RD groups, respectively (P = 0. 621). Conclusion Both allo-HSCTs from unrelated and sibling donors could successfully cure hematologic malignancies. Compared with RD group, URD group had a higher occurrence rate of Ⅲ ~ Ⅳ aGVHD and a relatively higher early infection rate but a relatively lower recurrence rate.关键词
造血干细胞移植/无关供者/同胞供者/移植物抗宿主病Key words
hematopoietic stem cell transplantation/ unrelated donor/ sibling donor /graft-versus-host disease分类
医药卫生引用本文复制引用
余正平,鲍文,丁家华,陈宝安,高冲,孙耘玉,程坚,王骏,赵刚,宋慧慧..不同供者来源异基因造血干细胞移植治疗恶性血液病69例疗效和预后分析[J].中国实用内科杂志,2012,32(11):862-864,后插1,4.基金项目
江苏省医学重点学科资助(2011-12) （2011-12）
